Jonathan (Jon) was trained in organic chemistry and has devoted his career to drug discovery and development, to find treatments and cures for patients suffering from chronic diseases such as cancer and autoimmune disease. Jon has spent 30 years as a drug hunter in both industry and academia (Merck, Celgene, Regulus and WARF Therapeutics (WT)) and has delivered 9 preclinical drug candidates, 2 of which have entered clinical trials. In 2018, Jon joined the Wisconsin Alumni Foundation (WARF) to build and lead a new academic biotech at the University of Wisconsin-Madison (UW-Madison) named WT. Our initial $50M funding was generously provided by WARF to promote drug discovery and translational activities on Campus. WT's mission is to partner with Principal Investigators on campus that are doing translational research, design novel drugs to sufficiently validated targets, and move them into clinical trials. WT is a global virtual biotech and has built collaborative partnerships with CROs to execute all phases of drug discovery. As part of WT's internal team, business development and licensing teams will seek venture capital investment or alternatively seek partnerships with biotech or pharma organizations for clinical trial execution and registration. As a non-profit organization, all revenue generated from WT will be granted back to the University to facilitate research on campus. In the first 5 years, WT has produced two preclinical candidates, one of which is a radiopharmaceutical drug, which will enter clinical trials in 12-18 months. Jon currently sits on the Advisory Boards at the UW School of Medicine and Public Health as well as the Cleveland Clinics Center for Therapeutics Discovery.